CHRS Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Coherus Oncology, Inc. had $42.2M of revenue in fiscal 2025, up 59.8% on the year before. Over five years, revenue changed β38.4% a year on average.
Last close Β· Oct 23, 2026
$1.01
3.8%Hi! I read Coherus Oncology, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+59.8%
Yes. Sales grew 59.8% last year.
Does it make a profit?
398.4%
Yes. It keeps 398.4% of every sale as profit.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Coherus Oncology, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 11, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 13, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 12, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 6, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Coherus Oncology, Inc. had $42.2M of revenue in fiscal 2025, up 59.8% on the year before. Over five years, revenue changed β38.4% a year on average. Its operating margin was β429.5%, up 327.1Β pts: of every 100 in sales, about β430 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Coherus Oncology, Inc. made $168M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Coherus Oncology, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $417M | $192M | $118M | $126M | $172M |
| Interest coverage | β11.5x | β7.9x | β5.0x | β18.6x | β20.1x |
| Current ratio | 3.6x | 2.7x | 1.4x | 1.2x | 1.5x |
| Quick ratio | 3.4x | 2.5x | 1.2x | 1.2x | 1.4x |
| Total assets | $679M | $481M | $630M | $449M | $258M |
| Total liabilities | $582M | $618M | $823M | $581M | $197M |
| Shareholders' equity | $97.7M | β$137M | β$193M | β$132M | $61.0M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Coherus Oncology, Inc. passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 1 / 7 | 5 / 8 | 4 / 8 | 2 / 8 | 1 / 8 | 2 / 8 | 3 / 8 | 5 / 8 |
| Accruals ratio | 70.2% | β22.2% | β38.2% | 24.2% | β3.5% | β32.8% | β8.7% | β11.3% | 9.1% | 86.7% |
| Altman Z'' | β10.18 | β20.17 | β43.01 | β1.34 | 3.67 | β3.25 | β9.61 | β9.10 | β13.65 | β20.15 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $190M | $1.6M | $0.0M | $356M | $476M | $327M | $211M | $257M | $26.4M | $42.2M |
| Gross profit | β | β | β | $339M | $438M | $269M | $141M | $98.3M | $17.7M | $28.4M |
| Research and development | $254M | $162M | $110M | $94.2M | $143M | $363M | $199M | $109M | $91.8M | $109M |
| Operating income | β$116M | β$232M | β$204M | $108M | $156M | β$264M | β$257M | β$203M | β$200M | β$181M |
| Interest expense | $8.0M | $9.6M | $9.7M | $17.6M | $21.2M | $23.0M | $32.5M | $40.5M | $10.7M | $9.0M |
| Pretax income | β | β$238M | β$209M | $92.8M | $136M | β$287M | β$292M | β$238M | β$215M | β$183M |
| Income tax | $0.0M | $0.0M | $0.0M | $2.9M | $3.5M | $0.0M | $0.0M | β$0.4M | $0.0M | $0.0M |
| Net income | β$127M | β$238M | β$209M | $89.8M | $132M | β$287M | β$292M | β$238M | $28.5M | $168M |
| Diluted EPS | β$3.04 | β$4.48 | β$3.22 | $1.23 | $1.62 | β$3.81 | β$3.76 | β$2.53 | $0.25 | $1.43 |
| Diluted shares | 0.04B | 0.05B | 0.07B | 0.07B | 0.08B | 0.08B | 0.08B | 0.09B | 0.11B | 0.12B |
| Cash flow | ||||||||||
| Cash from operations | β$253M | β$200M | β$159M | $28.4M | $154M | β$37.4M | β$241M | β$175M | β$20.4M | β$139M |
| Capital expenditure | $6.5M | $4.6M | $0.8M | $1.8M | $7.2M | $1.3M | $2.0M | $0.3M | β | β |
| Free cash flow | β$259M | β$205M | β$160M | $26.5M | $147M | β$38.7M | β$243M | β$175M | β | β |
| Depreciation and amortization | $3.0M | $3.4M | $3.2M | $3.3M | $2.9M | $3.5M | $3.6M | $3.2M | $1.6M | $1.3M |
| Stock-based compensation | $27.4M | $33.4M | $34.8M | $33.6M | $38.2M | $51.4M | $50.7M | $43.1M | $27.8M | $17.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $125M | $127M | $72.4M | $178M | $541M | $417M | $192M | $118M | $126M | $172M |
| Total debt | β | β | $0.0M | $73.7M | β | β | β | β | β | β |
| Finance lease liabilities | β | β | β | $0.0M | $1.4M | $1.2M | $2.6M | $1.1M | β | β |
| Current assets | $161M | $145M | $84.4M | $343M | $767M | $602M | $381M | $476M | $342M | $207M |
| Current liabilities | $56.4M | $28.4M | $33.3M | $115M | $146M | $165M | $139M | $332M | $283M | $140M |
| Inventory | β | β | $1.7M | $9.8M | $44.2M | $37.6M | $38.8M | $62.6M | $4.2M | $3.2M |
| Property and equipment, net | $10.8M | $12.8M | $6.7M | $5.8M | $10.1M | $7.8M | $8.8M | $5.1M | $2.6M | $1.3M |
| Goodwill | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | β | β |
| Intangible assets | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $3.6M | $5.9M | $71.7M | $24.8M | $20.0M |
| Total assets | $178M | $163M | $99.5M | $409M | $842M | $679M | $481M | $630M | $449M | $258M |
| Total liabilities | $159M | $132M | $138M | $304M | $561M | $582M | $618M | $823M | $581M | $197M |
| Shareholders' equity | $20.5M | $30.5M | β$38.6M | $105M | $281M | $97.7M | β$137M | β$193M | β$132M | $61.0M |
| Margins | ||||||||||
| Gross margin | β | β | β | 95.2% | 92.1% | 82.4% | 66.8% | 38.2% | 66.9% | 67.2% |
| Operating margin | β61.0% | β14,918.8% | β | 30.3% | 32.9% | β80.8% | β121.7% | β79.0% | β756.6% | β429.5% |
| EBITDA margin | β59.4% | β14,700.4% | β | 31.2% | 33.5% | β79.7% | β120.0% | β77.7% | β750.5% | β426.4% |
| Net margin | β67.0% | β15,306.6% | β | 25.2% | 27.8% | β87.9% | β138.2% | β92.5% | 108.0% | 398.4% |
| FCF margin | β136.3% | β13,165.7% | β | 7.5% | 30.9% | β11.9% | β115.2% | β68.1% | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β | 8,631.1% | β | β | β | β | β | β |
| Return on capital employed | β94.9% | β173.0% | β308.8% | 36.7% | 22.5% | β51.3% | β75.1% | β68.2% | β120.6% | β153.6% |
| Return on equity | β620.3% | β932.9% | β | 269.7% | 68.5% | β151.6% | β | β | β | β |
| Return on assets | β71.3% | β139.6% | β159.8% | 35.3% | 21.1% | β37.8% | β50.3% | β42.8% | 5.3% | 47.5% |
| Return on tangible equity | β750.6% | β883.0% | β | 88.4% | 47.7% | β307.8% | β | β | β | 409.7% |
| Growth | ||||||||||
| Revenue growth | β | β99.2% | β100.0% | β | 33.6% | β31.4% | β35.4% | 21.9% | β89.7% | 59.8% |
| Net income growth | β | β | β | β | 47.2% | β317.1% | β | β | β | 489.4% |
| EPS growth | β | β | β | β | 31.7% | β335.2% | β | β | β | 472.0% |
| FCF growth | β | β | β | β | 453.7% | β126.4% | β | β | β | β |
| Share count change | β | 26.8% | 22.4% | 12.5% | 14.1% | β9.6% | 2.9% | 21.3% | 21.7% | 2.3% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β0.9x | β | β | β | β | β | β |
| Debt / equity | β | β | β | 0.7x | β | β | β | β | β | β |
| Interest coverage | β14.5x | β24.3x | β21.1x | 6.1x | 7.4x | β11.5x | β7.9x | β5.0x | β18.6x | β20.1x |
| Current ratio | 2.9x | 5.1x | 2.5x | 3.0x | 5.3x | 3.6x | 2.7x | 1.4x | 1.2x | 1.5x |
| Quick ratio | 2.9x | 5.1x | 2.5x | 2.9x | 5.0x | 3.4x | 2.5x | 1.2x | 1.2x | 1.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.4% | 293.9% | β | 0.5% | 1.5% | 0.4% | 1.0% | 0.1% | β | β |
| Stock comp / revenue | 14.4% | 2,146.3% | β | 9.4% | 8.0% | 15.7% | 24.0% | 16.8% | 105.4% | 40.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 1.0 | 5.0 | 4.0 | 2.0 | 1.0 | 2.0 | 3.0 | 5.0 |
| Altman Z'' | β10.2 | β20.2 | β43.0 | β1.3 | 3.7 | β3.3 | β9.6 | β9.1 | β13.6 | β20.2 |
| Accruals ratio | 70.2% | β22.2% | β38.2% | 24.2% | β3.5% | β32.8% | β8.7% | β11.3% | 9.1% | 86.7% |
Source: SEC EDGAR XBRL filings (CIK 0001512762). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
